Systemic mastocytosis (SM) can be extremely heterogeneous and its treatment should be highly individualized. We reported a description of clinical management of an aggressive SM characterized at diagnosis by multiple organ involvement. The patient underwent to different lines of treatment, from standard chemotherapy to the novel tyrosine kinase inhibitor midostaurin.